FDB (First Databank) vs MedAware (2026)
Rules against a learned model in medication safety, with each side represented by a vendor that means it. FDB supplies the drug knowledge under most American prescribing systems, so most interaction and dose alerts a clinician has dismissed were built on its content. MedAware traces its founding to a prescribing error that killed a child, the kind of wrong drug pick no interaction rule can catch. It detects prescriptions that do not fit the patient rather than pairs of drugs that do not fit each other. These are layers, not alternatives. The rules catch the known hazard and generate the override fatigue. The outlier model catches what the rules cannot express, and it has to earn its alerts against an already tired prescriber.
- The drug knowledge underneath most American prescribing systems is this company's content, so its interaction and dose warnings are the baseline any additional layer is measured against.
- Content is embedded in the customer's own systems, which places hosting, residency and processing questions with the customer rather than with the supplier.
- Its newer products are framed conservatively, with a prescription agent queuing orders for clinician review rather than acting.
- It detects prescribing outliers a rule library cannot express, using outlier detection over longitudinal patient data.
- Hospital investigators at four sites have published on it, including Brigham and Women's and Massachusetts General, two of them with alerts firing live.
- Integration is named and confirmed by customers, including native operation inside an Epic pharmacy workflow at Ballad Health.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. FDB (First Databank) and MedAware are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | FDB (First Databank) | MedAware |
|---|---|---|
| Primary category | Medication Safety & Prescribing | Medication Safety & Prescribing |
| Founded | Not recorded | 2012 |
| Headquarters | South San Francisco, California, United States | Ra'anana, Israel |
| Website | fdbhealth.com | medaware.com |
Side by Side
Select any grade to read the note behind it.
Product updates
The latest logged changes from each vendor, newest first, each linked to its source.
FDB (First Databank)
-
Product / capability
FDB commercially deployed FDB Script Agent, an AI prescribing tool that converts ambient patient encounter dialogue directly into structured prescriptions.
Source
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
FDB, formerly First Databank, supplies the drug knowledge that sits underneath most medication decisions made in the United States. Its databases are integrated into the systems used by most hospitals, physician practices and pharmacies, which means that when a prescribing system warns about an interaction, a dose ceiling or a contraindication, the content behind that warning is frequently this company's rather than the software vendor's.
Source: AI Health Index, September 2026
MedAware is an Israeli company whose platform monitors prescribing for medication related risk using machine learning rather than the rule libraries that conventional medication decision support runs on. It was founded in 2012 after a nine year old asthma patient died because his physician selected the wrong drug from an electronic prescribing dropdown, an error no interaction rule was written to catch, because nothing in the prescription broke a rule; the drug was simply wrong for that patient.
Source: AI Health Index, September 2026
Questions buyers ask
How do FDB (First Databank) and MedAware handle patient data?
For FDB (First Databank), the licensed databases themselves are delivered inside customers' systems. The agentic products change the exposure: MedProof MCP serves knowledge in patient specific context, so patient details reach FDB on each tailored query, and Script Agent processes spoken clinical conversation.
Published material describes what the system does with the data clinically without describing what happens to the data operationally: MedAware publishes no retention period, no de identification practice, no minimum necessary scoping and no statement of whether customer data contributes to model development across institutions. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Which settings and specialties do FDB (First Databank) and MedAware cover?
In FDB (First Databank)'s case, the newer products deliberately address both ends of the workflow, with prescription automation aimed at ambulatory practice and order verification aimed at inpatient pharmacy.
For MedAware, inpatient acute care is confirmed by the Ballad Health pharmacy deployment, ambulatory care by the athenahealth Marketplace listing and by the Brigham and Women's and Massachusetts General outpatient datasets that produced the evidence base, and the company publishes material aimed at deprescribing in post acute and long term care. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
What evidence is published for FDB (First Databank) and MedAware?
With FDB (First Databank), the most notable absence is any comparison of whether agents grounded on FDB content give safer answers than agents that are not.
An earlier Harvard Medical School group (JAMIA, 2017) found about 75 percent of alerts valid in a 300 chart sample; that study states it was funded by MedAware, with the company taking no part in chart review or analysis. The opioid use disorder algorithm was validated against two expert opinions on more than 649,000 outpatient records at above 93 percent accuracy. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified September 20, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
A hospital running both will still see most of its alerts from the rules. FDB states its business associate role in its privacy notice; MedAware states no HIPAA status. Neither publishes a security attestation or trust center. MedAware publishes no results by age, sex, race, ethnicity, insurance status or site, which is the specific gap for an outlier detection model, since what counts as anomalous depends on the population the model learned from. FDB publishes the Hearst Health AI Principles but no results for its AI features. Neither publishes a price.